| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
(2R,3R,4S,5R)-2-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-5[(R)-hydroxy(phenyl)methyl]tetrahydrofuran-3,4-diol manufacturers
- LLY-283
-
-
2026-07-14
- CAS:2040291-27-6
- Purity: 99.22%
- Supply Ability: 10g
|
| | (2R,3R,4S,5R)-2-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-5[(R)-hydroxy(phenyl)methyl]tetrahydrofuran-3,4-diol Basic information |
| Product Name: | (2R,3R,4S,5R)-2-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-5[(R)-hydroxy(phenyl)methyl]tetrahydrofuran-3,4-diol | | Synonyms: | (2R,3R,4S,5R)-2-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-5[(R)-hydroxy(phenyl)methyl]tetrahydrofuran-3,4-diol;LM-5179;LLY-283
(LLY283);7H-Pyrrolo[2,3-d]pyrimidin-4-amine, 7-[(5R)-5-C-phenyl-β-D-ribofuranosyl]-;LLY-283 >=98% (HPLC);7-[(5R)-5-CPhenyl-β-D-ribofuranosyl]-7H-pyrrolo[2,3-d]pyrimidin-4-amine;(2R,3R,4S,5R)-2-(4-Amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-5-((R)-hydroxy(phenyl)methyl)tetrahydrofuran-3,4-diol;LLY-283, 10 mM in DMSO | | CAS: | 2040291-27-6 | | MF: | C17H18N4O4 | | MW: | 342.35 | | EINECS: | | | Product Categories: | | | Mol File: | 2040291-27-6.mol | ![(2R,3R,4S,5R)-2-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-5[(R)-hydroxy(phenyl)methyl]tetrahydrofuran-3,4-diol Structure](CAS/20180601/GIF/2040291-27-6.gif) |
| | (2R,3R,4S,5R)-2-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-5[(R)-hydroxy(phenyl)methyl]tetrahydrofuran-3,4-diol Chemical Properties |
| Boiling point | 688.9±55.0 °C(Predicted) | | density | 1+-.0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO: 60 mg/ml; Ethanol: 60 mg/ml | | form | A crystalline solid | | pka | 12.46±0.70(Predicted) | | color | White to off-white | | InChIKey | WWOOWAHTEXIWBO-QFRSUPTLSA-N | | SMILES | O[C@@H]1[C@@H]([C@H](O)C2=CC=CC=C2)O[C@@H](N3C(N=CN=C4N)=C4C=C3)[C@@H]1O |
| WGK Germany | WGK 3 | | Storage Class | 11 - Combustible Solids |
| | (2R,3R,4S,5R)-2-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-5[(R)-hydroxy(phenyl)methyl]tetrahydrofuran-3,4-diol Usage And Synthesis |
| Description | LLY-283 is an inhibitor of protein arginine methyltransferase 5 (PRMT5; IC50 = 22 nM). It is selective for PRMT5 over a panel of methyltransferases, including PRMT4, -6, and -7 at 1 μM. It reduces symmetric demethylation of SmBB'' in MCF-7 cells (IC50 = 25 nM) and inhibits proliferation of various breast, gastric, hematological, lung, skin, and ovarian cancer cell lines (IC50s = 3-30 nM). LLY-283 (20 mg/kg) inhibits tumor growth in an A375 mouse xenograft model. It also disrupts alternative splicing events in, and inhibits proliferation and self-renewal of, patient-derived glioblastoma stem cells and increases survival in an orthotopic patient-derived xenograft (PDX) mouse model. See the Structural Genomics Consortium (SGC) website for more information. | | Uses | LLY-283 is a potent, selective and oral protein arginine methyltransferase 5 (PRMT5) inhibitor, with an IC50 of 22 nM and a Kd of 6 nM for PRMT5:MEP50 complex, and shows antitumor activity. | | in vivo | LLY-283 (20 mg/kg; p.o., QD (once a day)) causes a significant inhibition on tumor growth in mice bearing A375 cells after treatment for 28 days[1]. | | IC 50 | PRMT5 | | References | [1] Zahid Q. Bonday, et al. LLY-283, a Potent and Selective Inhibitor of Arginine Methyltransferase 5, PRMT5, with Antitumor Activity. ACS Med. Chem. Lett., 2018, 9 (7), pp 612-617. |
| | (2R,3R,4S,5R)-2-(4-aminopyrrolo[2,3-d]pyrimidin-7-yl)-5[(R)-hydroxy(phenyl)methyl]tetrahydrofuran-3,4-diol Preparation Products And Raw materials |
|